TriSalus Q1 revenue falls 2.9% to $8.9M; 2026 revenue guidance revised to $54M-$57M
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million, down 2.9% from a year earlier, and revised its 2026 revenue guidance to $54 million to $57 million. Net income was $1.5 million, or $0.03 per share, but that result reflected $11.3 million of non-cash derivative gains, while the operating loss widened, so shareholders face a mixed picture.
Key points
- Q1 2026 revenue was $8.9 million, down 2.9% from $9.2 million in Q1 2025, which the company attributed mainly to its commercial expansion.
- Operating loss widened to $8.4 million from $7.3 million, and adjusted EBITDA loss widened to $5.8 million from $5.5 million.
- Net income attributable to common stockholders was $1.5 million, or $0.03 per share, versus a net loss of $11.1 million, or $(0.39) per share, a year earlier; the company cited $11.3 million of non-cash fair value gains on derivatives.
- 2026 revenue guidance was revised to $54 million to $57 million, citing lower Q1 revenue and delayed FDA clearance timing for TriNav Advance; cash totaled $56.6 million on March 31, 2026, after a $46.0 million gross equity raise.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.